首页> 美国卫生研究院文献>Oncotarget >Clinical and biological significance of circulating tumor cells circulating tumor DNA and exosomes as biomarkers in colorectal cancer
【2h】

Clinical and biological significance of circulating tumor cells circulating tumor DNA and exosomes as biomarkers in colorectal cancer

机译:循环肿瘤细胞循环肿瘤DNA和外来体作为结直肠癌生物标志物的临床和生物学意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CRC) has been the fourth leading cause of cancer-related mortality worldwide. Owing to clonal evolution and selection, CRC treatment needs multimodal therapeutic approaches and due monitoring of tumor progression and therapeutic efficacy. Liquid biopsy, involving the use of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, may offer a promising noninvasive alternative for diagnosis and for real-time monitoring of tumor evolution and therapeutic response compared to traditional tissue biopsy. Monitoring of the disease processes can enable clinicians to readily adopt a strategy based on optimal therapeutic decision-making. This article provides an overview of the significant advances and the current clinical and biological significance of CTCs, ctDNA, and exosomes in CRC, as well as a comparison of the main merits and demerits of these three components. The hurdles that need to be resolved and potential directions to be followed with respect to liquid biopsies for detection and therapy of CRC are also discussed.
机译:大肠癌(CRC)已成为全球癌症相关死亡率的第四大主要原因。由于克隆的进化和选择,CRC治疗需要多模式治疗方法以及对肿瘤进展和治疗效果的适当监测。与传统的组织活检相比,液体活检涉及循环肿瘤细胞(CTC),循环肿瘤DNA(ctDNA)和外泌体的使用,可能为诊断,实时监测肿瘤的进展和治疗反应提供有希望的非侵入性替代方法。疾病过程的监测可以使临床医生容易采用基于最佳治疗决策的策略。本文概述了CTC,ctDNA和外泌体在CRC中的重要进展以及当前的临床和生物学意义,并比较了这三个组件的主要优缺点。还讨论了有关液体活检以检测和治疗CRC所需要解决的障碍和可能遵循的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号